IL126895A - Antagonists to the D4 receptor of benzoxazinone dopamine derivatives - Google Patents

Antagonists to the D4 receptor of benzoxazinone dopamine derivatives

Info

Publication number
IL126895A
IL126895A IL12689597A IL12689597A IL126895A IL 126895 A IL126895 A IL 126895A IL 12689597 A IL12689597 A IL 12689597A IL 12689597 A IL12689597 A IL 12689597A IL 126895 A IL126895 A IL 126895A
Authority
IL
Israel
Prior art keywords
ylmethyl
benzo
oxazin
piperazin
phenyl
Prior art date
Application number
IL12689597A
Other languages
English (en)
Hebrew (he)
Other versions
IL126895A0 (en
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL126895A0 publication Critical patent/IL126895A0/xx
Publication of IL126895A publication Critical patent/IL126895A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12689597A 1996-05-29 1997-05-20 Antagonists to the D4 receptor of benzoxazinone dopamine derivatives IL126895A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1838396P 1996-05-29 1996-05-29
US4020897P 1997-03-06 1997-03-06
PCT/US1997/008524 WO1997045419A1 (en) 1996-05-29 1997-05-20 Benzoxazinone dopamine d4 receptor antagonists

Publications (2)

Publication Number Publication Date
IL126895A0 IL126895A0 (en) 1999-09-22
IL126895A true IL126895A (en) 2001-06-14

Family

ID=26691052

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12689597A IL126895A (en) 1996-05-29 1997-05-20 Antagonists to the D4 receptor of benzoxazinone dopamine derivatives

Country Status (37)

Country Link
EP (1) EP0906294B1 (zh)
JP (1) JP2000511534A (zh)
KR (1) KR20000016151A (zh)
CN (1) CN1074764C (zh)
AR (1) AR008372A1 (zh)
AT (1) ATE231846T1 (zh)
AU (1) AU731104B2 (zh)
BG (1) BG64049B1 (zh)
BR (1) BR9709630A (zh)
CA (1) CA2253406A1 (zh)
CO (1) CO4940505A1 (zh)
CZ (1) CZ384698A3 (zh)
DE (1) DE69718786T2 (zh)
DK (1) DK0906294T3 (zh)
EA (1) EA001486B1 (zh)
EE (1) EE03686B1 (zh)
ES (1) ES2191180T3 (zh)
GE (1) GEP20012389B (zh)
HK (1) HK1019737A1 (zh)
HN (1) HN1997000075A (zh)
HR (1) HRP970301B1 (zh)
HU (1) HUP9903758A3 (zh)
ID (1) ID17266A (zh)
IL (1) IL126895A (zh)
NO (1) NO312296B1 (zh)
NZ (1) NZ332737A (zh)
PA (1) PA8431101A1 (zh)
PE (1) PE69398A1 (zh)
PL (1) PL330195A1 (zh)
PT (1) PT906294E (zh)
RO (1) RO120845B1 (zh)
SI (1) SI0906294T1 (zh)
SK (1) SK282703B6 (zh)
SV (1) SV1997000047A (zh)
TW (1) TW542833B (zh)
UY (1) UY24569A1 (zh)
WO (1) WO1997045419A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177422B1 (en) 1996-05-29 2001-01-23 Warner-Lambert Company Benzoxazinone dopamine D4 receptor antagonists
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
US6291463B1 (en) 1998-06-30 2001-09-18 Neurogen Corporation 1-(Benzothiazol-2-yl)-4-(1-phenylmethyl) piperazines: dopamine receptor subtype specific ligands
WO2000000482A1 (en) * 1998-06-30 2000-01-06 Neurogen Corporation 1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines: dopamine receptor subtype specific ligands
EP1091949A2 (en) * 1998-06-30 2001-04-18 Neurogen Corporation 6-(4-arylalkylpiperazin-1-yl)benzodioxane and 6-(4-arylalkylpiperazin-1-yl)chromane derivatives: dopamine receptor subtype specific ligands
US6177566B1 (en) 1998-06-30 2001-01-23 Neurogen Corporation 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
DE19844291A1 (de) * 1998-09-18 2000-03-23 Schering Ag Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
DE60127434T2 (de) 2000-10-26 2007-11-29 Smithkline Beecham P.L.C., Brentford Benzoxazinonderivative, deren herstellung und verwendung
GB0203804D0 (en) 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
GB0209244D0 (en) * 2002-04-23 2002-06-05 Glaxo Group Ltd Compounds
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
ES2232292B1 (es) * 2003-07-30 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Compuestos sulfonamidicos derivados de benzoxazinona, su preparacion y uso como medicamentos.
CN100455573C (zh) * 2005-11-11 2009-01-28 华东理工大学 一种制备1,4-苯并噁唑嗪-3-酮化合物的微波合成方法
KR200482995Y1 (ko) 2015-08-19 2017-03-23 이현진 물 공급부를 구비하는 얼음 트레이
CA3215823A1 (en) * 2021-04-23 2022-10-27 Peng Gao Heterocyclic derivative inhibitor and preparation method therefor and application thereof
WO2023207283A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Compounds as parp1 inhibitiors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4613598A (en) * 1984-03-13 1986-09-23 Mitsubishi Chemical Industries Limited Piperazine derivatives and their acid addition salts
EP0233728A1 (en) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
US5523299A (en) * 1992-08-06 1996-06-04 Smithkline Beecham Plc 5-(2-oxyphenyl)-pyrrole derivatives as dopamine D3 receptor antagonists

Also Published As

Publication number Publication date
JP2000511534A (ja) 2000-09-05
SI0906294T1 (en) 2003-04-30
WO1997045419A1 (en) 1997-12-04
ES2191180T3 (es) 2003-09-01
EE03686B1 (et) 2002-04-15
AU3072797A (en) 1998-01-05
TW542833B (en) 2003-07-21
SV1997000047A (es) 1998-08-13
NO312296B1 (no) 2002-04-22
DE69718786D1 (de) 2003-03-06
GEP20012389B (en) 2001-03-25
CA2253406A1 (en) 1997-12-04
BG64049B1 (bg) 2003-11-28
ATE231846T1 (de) 2003-02-15
NO985531L (no) 1998-11-27
HUP9903758A2 (hu) 2000-06-28
PT906294E (pt) 2003-06-30
EE9800417A (et) 1999-06-15
BR9709630A (pt) 1999-08-10
PE69398A1 (es) 1998-12-02
HRP970301B1 (en) 2002-08-31
KR20000016151A (ko) 2000-03-25
CZ384698A3 (cs) 1999-03-17
EA001486B1 (ru) 2001-04-23
HN1997000075A (es) 1997-07-30
PL330195A1 (en) 1999-04-26
DK0906294T3 (da) 2003-05-05
ID17266A (id) 1997-12-18
BG102959A (en) 1999-08-31
AR008372A1 (es) 2000-01-19
SK282703B6 (sk) 2002-11-06
EA199800987A1 (ru) 1999-06-24
EP0906294B1 (en) 2003-01-29
CO4940505A1 (es) 2000-07-24
EP0906294A1 (en) 1999-04-07
SK162798A3 (en) 1999-06-11
RO120845B1 (ro) 2006-08-30
UY24569A1 (es) 2001-08-27
NO985531D0 (no) 1998-11-27
NZ332737A (en) 2000-06-23
AU731104B2 (en) 2001-03-22
HK1019737A1 (en) 2000-02-25
CN1219930A (zh) 1999-06-16
DE69718786T2 (de) 2003-10-23
IL126895A0 (en) 1999-09-22
HUP9903758A3 (en) 2000-07-28
CN1074764C (zh) 2001-11-14
HRP970301A2 (en) 1998-04-30
PA8431101A1 (es) 2001-12-14

Similar Documents

Publication Publication Date Title
IL126895A (en) Antagonists to the D4 receptor of benzoxazinone dopamine derivatives
KR970000953B1 (ko) 티아디아지논 화합물
CN103429590B (zh) 作为bace1和/或bace2抑制剂的1,4硫氮杂*/砜
CA1287351C (en) Aromatic 2-aminoalkyl-1,2-benzoisothiazol-3(2h)one-1, 1-dioxide derivatives
US20080064871A1 (en) Production Method of Nitrogen-Containing Fused Ring Compounds
IL193070A (en) History of the Trubicyclic Sulphonamide, Preparations Including Them, Process for their Preparation and Use in the Preparation of Medicines for the Treatment of Diseases Modulated by l-cpt1 Inhibitors
CZ20012551A3 (cs) Sloučeniny triazolu a jejich pouľití
MX2013001542A (es) Derivado de triazina y composicion farmaceutica que tiene actividad analgesica que comprende el mismo.
DK149344B (da) Analogifremgangsmaade til fremstilling af 4-hydroxy-2h-1,2-benzothiazin-3-carboxamid-1,1-dioxider
KR20220141328A (ko) 소분자 sting 길항제
JP2911967B2 (ja) 新規な5,11―ジヒドロ―6H―ジピリド〔3,2―b:2′,3′―e〕〔1,4〕ジアゼピン―6―オンおよび―チオン、および該化合物を含有するAIDS予防または治療剤
BRPI0709101A2 (pt) derivados de triazolona e medicamento e agente terapêutico e/ou profilático compreendendo os mesmos
IE60246B1 (en) Thiolactam-n-acetic acid derivatives, their production and use
JPH02149579A (ja) ヘテロ環置換アルコキシクマリン、その製造方法およびこれを含有する治療剤
US6177422B1 (en) Benzoxazinone dopamine D4 receptor antagonists
CA2006769C (en) 2-and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo [1,2,3,-de] -1,4-benzoxazines useful as analgesic agents
CA2120301A1 (en) Thiadiazinones
NO309477B1 (no) Nye heterocykliske aminometylforbindelser, fremgangsmåte ved fremstilling av dem og farmasöytiske sammensetninger som inneholder dem
US5916914A (en) Compounds and method of treating psychosis and schizophrenia
CZ281377B6 (cs) Thiadiazinony, způsob jejich výroby a farmaceutické přípravky na jejich bázi
JP4025377B2 (ja) 3−アルコキシカルボニル−チアジアジノン化合物
DK175200B1 (da) Broforbundne bicycliske imider med en 4-[4-(3-benzisothiazolyl)-1-piperazinyl]butylgruppe knyttet til imidnitrogenatomer og antipsykotisk farmaceutiske præparater indeholdende disse
US6087364A (en) Dopamine D4 receptor antagonists
US5922719A (en) Coumarin dopamine D4 receptor antagonists
DK149106B (da) Analogifremgangsmaade til fremstilling af 1,2,4-oxadiazinderivater eller farmaceutisk acceptable syreadditionssalte eller kvaternaere salte deraf samt 1,2,4-oxadiazolin-5-oner til anvendelse ved fremgangsmaaden

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees